Zilovertamab Vedotin
Progesterone-receptor-positive Breast Cancer
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)antibody_drug_conjugatePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Progesterone-receptor-positive Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TAMOXIFEN Jennifer Lee Caswell-Jin | Phase 2 | BB |
Letrozole Ruth O'Regan | Phase 2 | BB |
Cyclophosphamide University of Washington | Phase 2 | B |
FILGRASTIM University of Washington | Phase 2 | B |
Palbociclib Abramson Cancer Center at Penn Medicine | Phase 2 | B |
View all 37 →
Same molecule, other indications
Zilovertamab Vedotin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →